Jennifer Brown, MD of Dana Farber, discusses a promising study that combines Ibrutinib with TGR-1202 and its results at the 58th ASH Annual Meeting in San Diego, CA.
Ibrutinib and TGR-1202 Combo Encouraging Relapsed Leukemia or Lymphoma
Advertisement